Value-Based Cancer Care Issues


April 2015, Vol 6, No 3

Abstracts to Be Presented at the Fifth Annual Conference of the Association for Value-Based Cancer Care

AVBCC 2015 5th Annual Conference Abstracts

  • 4-Year Employer Trends and Value-Based Oncology Coverage–Related Findings from a National Employer Survey
  • Willingness to Pay for Treatment Among Women with Metastatic Breast Cancer
  • Current Practices in the Use of Next-Generation Sequencing: A Steep Learning Curve?
  • Using Data to Improve Quality of Care and Process Sheryl Riley
  • Treatment-Sequencing Patterns of Novel Agents in Patients with Prostate Cancer
  • Prostate Cancer Assay Improves Treatment Decisions for Patients with Early-Stage Disease
  • Defining Value in Oncology: Perspectives from Patients with Metastatic Breast Cancer
  • Examining Experiences of Patients Currently Being Treated with Abiraterone Acetate for Metastatic Castrate-Resistant...
  • Myeloid Growth Factor Utilization in a Commercial and Medicare Population: Phase 1 of a Quality Improvement Initiative
  • Improving the Awareness, Identification, and Management of Sarcopenic Obesity: An Evidence-Based Toolbox
  • Measuring the Value of Telephone Distress Screening and Referral on Resource Utilization and Distress in Patients with...
  • Demonstrating Return on Investment for Stakeholders in a Care Coordination Program
  • Budget Impact Analysis of Abiraterone Acetate plus Prednisone versus Enzalutamide for the Treatment of Patients with...
  • Budget Impact Analysis of Ibrutinib for Patients with Previously Treated Mantle-Cell Lymphoma
  • Cost-Effectiveness of Octreotide LAR versus Lanreotide Depot in the Treatment of Metastatic Gastrointestinal...
  • Patterns of Utilization of Bortezomib Retreatment in Patients with Relapsed and/or Refractory Multiple Myeloma Who...
  • Utilization Beyond Traditional Oncology Care Management: Utilizing Multiple Data Sets and Clinical Tools to Improve the...
  • Utilization of the New Agents Carfilzomib and Pomalidomide in Relapsed and/or Refractory Multiple Myeloma: Analysis...
  • Economic Impact of a Novel Circulating Tumor DNA Test for Third-Generation EGFR TKI Biomarker Testing in NSCLC
[ Read More ]

NCCN Panel Addresses Value-Based Care in Oncology

Wayne Kuznar

Economics of Cancer Care

Hollywood, FL—Value-based decision-making at the bedside can be fraught with obstacles, with no clear agreement on what constitutes value, and for whom. In addition, the myriad insurance plans preclude uniform treatment strategies, despite clinical pathways and guidelines intended to reduce variation in care. Finally, value is becoming more difficult to achieve in oncology as each benefit becomes more expensive, with the cost of new therapies outpacing inflation. [ Read More ]

ASCO’s Annual Report: Major Advances in Oncology and the Challenge of Value-Based Care

Eileen Koutnik-Fotopoulos

Health Policy

Significant gains in cancer research and prevention have led to longer survival, improved quality of life, and decreased disease burden. The 2015 annual report on “Clinical Cancer Advances” from the American Society of Clinical Oncology (ASCO) outlines the biggest advances made in oncology, and for the first time designates one cancer as the Advance of the Year, as well as emphasizing the ongoing challenge of value-based care. [ Read More ]

Value Propositions – April 2015

Value Propositions

  • Genetic Mutations Rampant in Pancreatic Cancers: Targeted Drugs Hold Key to Therapy
  • Tetanus Booster Against Cytomegalovirus Enhances the Immune System, Improves Survival in Glioblastoma
  • Polygenic Risk Score for Breast Cancer on the Horizon
[ Read More ]

Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with Renal-Cell Carcinoma

Chase Doyle

Economics of Cancer Care

Hollywood, FL—Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the 2015 National Comprehensive Cancer Network (NCCN) conference, the newer drug, pazopanib, may have some advantage in terms of total cost of care, but survival outcomes were exactly the same. [ Read More ]

Insurance Status Impacts Ability to Travel for Care

Economics of Cancer Care

Orlando, FL—Patients undergoing complex oncologic procedures, such as rad­ical cystectomy, radical prostatectomy, or percutaneous nephrolithotomy, are more likely to travel outside of their regions if they have private insurance, potentially reflecting better access to care based on income, according to findings presented at the 2015 Genitourinary Cancers Symposium. [ Read More ]

Millions in Savings by Using Prolaris Test in All Men with Localized Prostate Cancer

Alice Goodman

Economics of Cancer Care

Orlando, FL—Significant cost-savings in treating patients with prostate cancer could be achieved in the US healthcare system with the use of the cell-cycle progression (CCP) gene-expression assay called Prolaris (from Myriad Genetics Laboratories), according to a poster from E. David Crawford, MD, Professor of Surgery and Radiation Oncology, University of Colorado, Aurora, and colleagues, presented at the 2015 Genitourinary Cancers Symposium. [ Read More ]

Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future

Wayne Kuznar

NCCN Conference Highlights

Hollywood, FL—Watch and wait remains the standard of care for patients with asymptomatic early-stage chronic lymphocytic leukemia (CLL), even for high-risk patients, but once therapy is indicated, targeted agents may supplant chemotherapy in the first-line treatment setting, said William G. Wierda, MD, PhD, Center Medical Director, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2015 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer

Wayne Kuznar

NCCN Conference Highlights

Hollywood, FL—A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment if needed, said Peter G. Shields, MD, Deputy Director, Comprehensive Cancer Center, James Cancer Hospital, Columbus, OH, at the 2015 National Comprehensive Cancer Network (NCCN) conference. [ Read More ]

Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel

Wayne Kuznar

NCCN Conference Highlights

Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guideline allows for the upfront use of docetaxel (Taxotere) in some men with castration-resistant prostate cancer (CRPC). This and other systemic therapies represent the most significant changes in the updated guideline for the treatment of patients with metastatic CRPC, said Andrew J. Armstrong, MD, ScM, Co­-Leader, Genitourinary Oncology Research Program, Duke Cancer Institute, Durham, NC, at the 2015 NCCN annual conference. [ Read More ]

Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach

Interview with the Innovators

The current generation of oncologists has witnessed great advances in our understanding of tumor biology and biomarkers linked to treatments. Those advances started with research, but disseminating this information can be difficult given the myriad of obstacles in adoption to practice. The science behind these advances is fascinating and excites those in medicine with the possibility of providing meaningful, life-altering care to patients. But still there exists the reality of the vetting of each new discovery, starting with niche use among the early users, before it gets adopted more broadly. [ Read More ]

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Loretta Fala

Drug Updates

Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States.1 There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014.1 Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years),1 and it occurs 2 to 3 times more often in women than in men.2 The incidence of thyroid cancer has risen steadily in recent years.3 Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased.3 [ Read More ]

Clinical Utility of Genomic Biomarker Tests Questioned

Alice Goodman

Personalized Medicine

Orlando, FL—An independent review of the literature suggests that 3 biomarker tests developed for prostate cancer have yet to justify their utility in randomized clinical trials. The 3 tests in question—Prolaris, Decipher, and Oncotype DX for prostate cancer—are being used in practices around the country, cost approximately $3500 per test, and are reimbursable by Medicare depending on the state. [ Read More ]